Opinion|Videos|July 16, 2024
Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL
John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Explore the logistics and best practices aimed at optimizing therapeutic response, minimizing potential adverse events, and maximizing off-treatment benefits.
- How do you initiate venetoclax therapy in your practice, including titration and management of potential AEs and risk of tumor lysis syndrome?
- What insights/implications do recent real-world data provide?
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
The NMPA has approved pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer
3
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
4
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
5